US$ 27.76
glp 1 drugs stocks Novo Nordisk Surges 7.3% as FDA Approves First Oral Weight-Loss GLP-1 Drug Exploring GLP-1 Stocks - Weight
Description
This process keeps food in the digestive system for longer making people feel fuller for longer, thus reducing appetite and inducing weight loss

20222023: Tirzepatide and the SURMOUNT Trials Tirzepatide (Mounjaro) raised the bar

These patients often experience multiple comorbidities, such as diabetes and cardiovascular disease, where GLP-1 therapies offer additional health benefits beyond weight loss

Its not just physical its emotional too
